Hybio Pharmaceutical Co., Ltd. (SHE:300199)
China · Delayed Price · Currency is CNY 21.86
-0.45 (-2.02%)
Oct 30, 2026, 3:04 PM CST
Hybio Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Net Income | 401.86 | 36.57 | -173.65 | -513.88 | -370.55 | 30.81 |
Depreciation & Amortization | 130.36 | 131.17 | 148.27 | 155.54 | 140.59 | 135.78 |
Other Amortization | 8.68 | 7.86 | 2.65 | 4.9 | 3.89 | 3.7 |
Loss (Gain) From Sale of Assets | -0.62 | -0.62 | -42.78 | 0.51 | -3.41 | -35.2 |
Asset Writedown & Restructuring Costs | 12.45 | 12.45 | 82.43 | 99.94 | 23.05 | 75.31 |
Loss (Gain) From Sale of Investments | -1.5 | -1.5 | -1.55 | -43.83 | 86.06 | -372.29 |
Provision & Write-off of Bad Debts | 7.07 | 7.07 | 5.55 | 2.96 | 35.95 | 70.22 |
Other Operating Activities | -141.97 | 115.67 | 136.1 | 166.02 | 142.83 | 127.31 |
Change in Accounts Receivable | -49.51 | -49.51 | 26.37 | 121.2 | -60.54 | 17.56 |
Change in Inventory | -35.97 | -35.97 | -80.07 | 20.98 | -57.7 | 19.28 |
Change in Accounts Payable | 2.25 | 2.25 | 78.32 | -17.12 | 59.6 | 81 |
Change in Other Net Operating Assets | - | - | -16.53 | -0.03 | 16.56 | - |
Operating Cash Flow | 341.56 | 233.9 | 164.71 | -3.54 | 15.81 | 156.83 |
Operating Cash Flow Growth | -1.66% | 42.01% | - | - | -89.92% | 226.79% |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Capital Expenditures | -326.79 | -234.35 | -115.84 | -81.76 | -189.85 | -199 |
Sale of Property, Plant & Equipment | 0.55 | 0.43 | 45.53 | 1.07 | 47.49 | 0.14 |
Cash Acquisitions | - | - | - | - | -0.1 | -3.92 |
Divestitures | 0.4 | 1.85 | - | - | -1.93 | - |
Investment in Securities | -6.88 | 5.4 | 0.3 | 228.37 | 195.29 | 21.2 |
Other Investing Activities | -0.97 | - | - | 0.03 | 0.82 | 3.19 |
Investing Cash Flow | -333.69 | -226.67 | -70.01 | 147.71 | 51.72 | -178.39 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Short-Term Debt Issued | - | 28.5 | 190.4 | 12 | 5 | - |
Long-Term Debt Issued | - | 1,578 | 1,339 | 1,378 | 537.29 | 1,457 |
Total Debt Issued | 1,711 | 1,606 | 1,529 | 1,390 | 542.29 | 1,457 |
Short-Term Debt Repaid | - | -84.5 | -207.4 | - | - | - |
Long-Term Debt Repaid | - | -1,638 | -1,541 | -1,173 | -495.09 | -1,644 |
Lease Payments | -1.01 | -1.01 | -1.01 | -7.86 | -12.61 | -12.61 |
Total Debt Repaid | -1,637 | -1,723 | -1,749 | -1,173 | -495.09 | -1,644 |
Net Debt Issued (Repaid) | 73.66 | -116.7 | -219.55 | 216.25 | 47.2 | -187.81 |
Issuance of Common Stock | - | - | 2.14 | - | - | - |
Repurchase of Common Stock | -0.1 | - | - | - | - | - |
Common Dividends Paid | -97.4 | -94.84 | -111.75 | -117.9 | -114.8 | -115.64 |
Other Financing Activities | 34.91 | 187.57 | -16.33 | -2.5 | -3.5 | 49.79 |
Financing Cash Flow | 11.07 | -23.96 | -345.48 | 95.85 | -71.11 | -253.67 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Foreign Exchange Rate Adjustments | -5.84 | 1.48 | 3.38 | 0.92 | 2.07 | -1.58 |
Net Cash Flow | 13.09 | -15.25 | -247.4 | 240.94 | -1.51 | -276.81 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 14.76 | -0.45 | 48.87 | -85.3 | -174.04 | -42.17 |
Free Cash Flow Growth | -88.55% | - | - | - | - | - |
Free Cash Flow Margin | 0.97% | -0.05% | 8.28% | -19.77% | -24.71% | -5.73% |
Free Cash Flow Per Share | 0.02 | - | 0.06 | -0.10 | -0.20 | -0.04 |
Levered Free Cash Flow | -28.12 | -98.71 | 61.55 | -54.53 | -176.94 | -190.2 |
Unlevered Free Cash Flow | 25.47 | -37.44 | 128.11 | 20.76 | -112.4 | -135.25 |
Free Cash Flow After Leases | 13.76 | -1.45 | 47.87 | -93.16 | -186.65 | -54.78 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash Income Tax Paid | 0.94 | 6.3 | 7.42 | 59.68 | 41.6 | 65.12 |
Change in Working Capital | -74.77 | -74.77 | 7.7 | 124.3 | -42.62 | 121.2 |